Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the worlds only… [+1251 chars]
(marketscreener.com) Regulatory News: ABIONYX Pharma , a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announces its financial calendar
Related
Share this page
Guest Posts by Easy Branches
